143 related articles for article (PubMed ID: 17068841)
1. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
4. Rational design of new bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of types I and II dehydroquinase.
Le Sann C; Gower MA; Abell AD
Mini Rev Med Chem; 2004 Sep; 4(7):747-56. PubMed ID: 15379642
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
Sánchez-Sixto C; Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2005 Jul; 48(15):4871-81. PubMed ID: 16033267
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
[TBL] [Abstract][Full Text] [Related]
9. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
10. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
12. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 3-alkyl enol mimics inhibitors of type II dehydroquinase: factors influencing their inhibition potency.
Blanco B; Sedes A; Peón A; Lamb H; Hawkins AR; Castedo L; González-Bello C
Org Biomol Chem; 2012 May; 10(18):3662-76. PubMed ID: 22447158
[TBL] [Abstract][Full Text] [Related]
14. 2-substituted-3-dehydroquinic acids as potent competitive inhibitors of type II dehydroquinase.
Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2009 Dec; 4(12):1980-4. PubMed ID: 19856378
[No Abstract] [Full Text] [Related]
15. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
Peón A; Coderch C; Gago F; González-Bello C
ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
[TBL] [Abstract][Full Text] [Related]
17. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors.
Blanco B; Sedes A; Peón A; Otero JM; van Raaij MJ; Thompson P; Hawkins AR; González-Bello C
J Med Chem; 2014 Apr; 57(8):3494-510. PubMed ID: 24689821
[TBL] [Abstract][Full Text] [Related]
18. (1R,4S,5R)-3-Fluoro-1,4,5-trihydroxy-2-cyclohexene-1-carboxylic acid: the fluoro analogue of the enolate intermediate in the reaction catalyzed by type II dehydroquinases.
Frederickson M; Roszak AW; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2004 Jun; 2(11):1592-6. PubMed ID: 15162210
[TBL] [Abstract][Full Text] [Related]
19. The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction.
Gourley DG; Shrive AK; Polikarpov I; Krell T; Coggins JR; Hawkins AR; Isaacs NW; Sawyer L
Nat Struct Biol; 1999 Jun; 6(6):521-5. PubMed ID: 10360352
[TBL] [Abstract][Full Text] [Related]
20. Parallel solid-phase synthesis and evaluation of inhibitors of Streptomyces coelicolor type II dehydroquinase.
González-Bello C; Lence E; Toscano MD; Castedo L; Coggins JR; Abell C
J Med Chem; 2003 Dec; 46(26):5735-44. PubMed ID: 14667226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
